# Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model

“Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model” (2019), by Elizabeth E. Spangenberg et al. Neuroscience research paper. Original abstract below, unchanged. A free PDF is available.

- Authors: Elizabeth E. Spangenberg, Paul L. Severson, Lindsay A. Hohsfield, Joshua D. Crapser, Jiazhong Zhang, Elizabeth A. Burton, Ying Zhang, Wayne R. Spevak, JACK T. S. LIN, Nicole Y. Phan et al.
- Published: August 21, 2019
- Field: Neuroscience
- DOI: https://doi.org/10.1038/s41467-019-11674-z
- Free PDF: https://www.nature.com/articles/s41467-019-11674-z.pdf

## Abstract

Many risk genes for the development of Alzheimer's disease (AD) are exclusively or highly expressed in myeloid cells. Microglia are dependent on colony-stimulating factor 1 receptor (CSF1R) signaling for their survival. We designed and synthesized a highly selective brain-penetrant CSF1R inhibitor (PLX5622) allowing for extended and specific microglial elimination, preceding and during pathology development. We find that in the 5xFAD mouse model of AD, plaques fail to form in the parenchymal space following microglial depletion, except in areas containing surviving microglia. Instead, Aβ deposits in cortical blood vessels reminiscent of cerebral amyloid angiopathy. Altered gene expression in the 5xFAD hippocampus is also reversed by the absence of microglia. Transcriptional analyses of the residual plaque-forming microglia show they exhibit a disease-associated microglia profile. Collectively, we describe the structure, formulation, and efficacy of PLX5622, which allows for sustained microglial depletion and identify roles of microglia in initiating plaque pathogenesis.

Canonical page: https://nerdi.pages.dev/paper/W2969940182
Read three real papers a day in Nerdi (iPhone): https://apps.apple.com/app/apple-store/id6813826387?pt=128757794&ct=web-paper&mt=8